menu
    • menu
    [{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AR-701","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AR-711","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AR-711","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AR-711","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Suvratoxumab","moa":"Staphylococcus aureus alpha toxin binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intradermal Injection","sponsorNew":"Aridis Pharmaceuticals \/ Aridis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Aridis Pharmaceuticals"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"AR-701","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pharmaceuticals \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Mapp Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"MBP134","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aridis Pharmaceuticals \/ Aridis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Aridis Pharmaceuticals \/ Aridis Pharmaceuticals"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Gallium Citrate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Termination","leadProduct":"Suvratoxumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"","sponsorNew":"Aridis Pharmaceuticals \/ MedImmune","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ MedImmune"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Aridis Pharmaceuticals

    Menu

    Aridis Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single C...

                            Details : AR-301 (tosatoxumab) is a fully human IgG1 monoclonal antibody that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus being deve...

                            Brand Name : AR-301

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 17, 2023

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aridis AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDAs Qualified Infectious Diseases P...

                            Details : AR-301 (tosatoxumab), a fully human IgG1 monoclonal antibody that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus, is being de...

                            Brand Name : AR-301

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 12, 2023

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aridis Pharmaceuticals' AR-301 Eligible for Consideration Under FDA's Limited Population Pathway for Antibacte...

                            Details : AR-301 (tosatoxumab) is a fully human IgG1 monoclonal antibody that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus being deve...

                            Brand Name : AR-301

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 20, 2023

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study...

                            Details : AR-301 (tosatoxumab) is a fully human IgG1 monoclonal antibody that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus being deve...

                            Brand Name : AR-301

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 31, 2023

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Suvratoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $126.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            AstraZeneca Pulls Pneumonia Collab With Aridis Over Allegations Of A Missed Payment

                            Details : AstraZeneca terminated the collaboration with Aridis for the licensing of the AR-320 (suvratoxumab), a fully human, half-life extended IgG1 monoclonal antibody targeting S. aureus alpha toxin.

                            Brand Name : AR-320

                            Molecule Type : Large molecule

                            Upfront Cash : $11.0 million

                            March 31, 2023

                            Lead Product(s) : Suvratoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $126.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gallium Citrate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients

                            Details : AR-501 is a novel inhaled formulation of gallium citrate with broad-spectrum anti-infective activity involving iron acquisition and metabolism, is being developed to treat chronic lung infections in cystic fibrosis (CF) patients.

                            Brand Name : AR-501

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 13, 2023

                            Lead Product(s) : Gallium Citrate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment o...

                            Details : AR-301 is a fully human IgG1 monoclonal antibody that targets S. aureus alpha-toxin (virulence factor that is secreted by both MRSA and MSSA). It is designed to protect against alpha-toxin mediated destruction of host cells, preserving a functional host ...

                            Brand Name : AR-301

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 25, 2023

                            Lead Product(s) : Tosatoxumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gallium Citrate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update

                            Details : AR-501 is a novel inhaled formulation of gallium citrate with broad-spectrum anti-infective activity involving iron acquisition and metabolism, is being developed to treat chronic lung infections in cystic fibrosis (CF) patients.

                            Brand Name : AR-501

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 17, 2023

                            Lead Product(s) : Gallium Citrate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gallium Citrate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $12.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CF Foundation Invests Up to $4.85 Million in Aridis Pharmaceuticals for Testing of Anti-Infective

                            Details : AR-501 is a novel, small molecule and an inhalable form of gallium citrate, which acts as an iron analog to starve bacteria of iron. Gallium is believed to inhibit multiple iron-dependent synthetic and metabolic pathways required for pathogenicity.

                            Brand Name : AR-501

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 12, 2022

                            Lead Product(s) : Gallium Citrate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $12.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Aridis Pharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBP134

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Recipient : Mapp Biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal ...

                            Details : The pan-Ebola program, MBP134, is a two mAb cocktail that has demonstrated effectiveness against Sudan virus (SUDV), Zaire Ebola virus (EBOV), Bundibugyo virus (BDBV), Taï Forest virus (TAFV), Reston virus (RESTV), and Bombali ebolavirus (BOMV).

                            Brand Name : MBP134

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 05, 2022

                            Lead Product(s) : MBP134

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Recipient : Mapp Biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth